Form 8-K - Current report:
SEC Accession No. 0001193125-26-187641
Filing Date
2026-04-28
Accepted
2026-04-28 17:02:08
Documents
9
Period of Report
2026-04-28
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K janx-20260428.htm   iXBRL 8-K 47211
  Complete submission text file 0001193125-26-187641.txt   158910

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT janx-20260428.xsd EX-101.SCH 29260
12 EXTRACTED XBRL INSTANCE DOCUMENT janx-20260428_htm.xml XML 4721
Mailing Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130
Business Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130 (858) 751-4493
Janux Therapeutics, Inc. (Filer) CIK: 0001817713 (see all company filings)

EIN.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40475 | Film No.: 26909028
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)